Clinical and epidemiological differences of lymphomas of the central nervous system. 10 years of experience in a reference center in Mexico.

Solapas principales

Córdoba M.1 Del Castillo J.1, Loya I.2 Ángeles J.3 Medina O.1 Ochoa D.1, Vicuña R.4, García U.5

ABSTRACT

 

            Background: Central nervous system lymphoma (CNSL) is a non-Hodgkin lymphoma (NHL) that is either primary or secondary due to infiltration from elsewhere. Primary central nervous system lymphoma (PCNSL) is a relatively rare disease accounting for 2–6% of all primary brain malignancies and 1–2% of NHL. Meanwhile, the incidence of secondary central nervous system lymphoma (SCNSL) ranges from 1 to >10%, with a median survival rate of 2–10 months with chemotherapy. To describe the epidemiological characteristics and differences in patients with CNSL in our population. A retrospective search of electronic health records of admitted patients at our institution between October 1999 and October 2017 was performed with the diagnosis of CNSL. Demographic and survival data were obtained and analyzed. We found 23 patients with CNSL (56.5%, PCNSL; 43.5%, SCNSL). Diagnostic mean age was 64.38 ± 12.7 years for PCNSL and 52.3 ± 16.2 years for SCNSL patients. (p = 0.59). Mean duration from the first symptom to complete diagnosis was 2.95 ± 1.71 months for PCNSL and 0.60 ± 0.70 months for SCNSL (p = 0.003). The overall survival (OS) was 2.06 ± 0.41 years for PCNSL and 1.13 ± 0.14 years for SCNSL. Progression-free survival (PFS) in PCNSL was 2.02 ± 0.41 years and 1.08 ± 0.20 years in SCNSL. We found no statistically significant differences in demographic and clinical symptoms between both subgroups. The results indicated to us that making a differentiation between the two types of lymphomas only based on clinical findings or demographics is insufficient.

Key Words: Lymphoma; Primary Central Nervous System Lymphoma; Epidemiology; Secondary Central Nervous System Lymphoma; Neurosurgical Oncology; Epidemiology.

 


  1. Residente de Neurocirugía, Hospital Central Sur de Alta Especialidad de PEMEX, Ciudad de México, México.
  2. Investigador Departamento de Oncología, Centro Médico Nacional 20 de Noviembre, Ciudad de México, México.
  3. Médico Internista, Hospital Ángeles del Pedregal, Ciudad de México, México.
  4. Médico Adscrito servicio de Patología, Hospital Central Sur de Alta Especialidad de PEMEX, Ciudad de México, México.
  5. Jefe del Departamento de Neurocirugía, Hospital Central Sur de Alta Especialidad de PEMEX, Ciudad de México, México.

VER TEXTO COMPLETO